Sanofi completes acquisition of Vicebio, expanding respiratory vaccine portfolio.

Sanofi has completed its acquisition of Vicebio Ltd, gaining an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). The acquired vaccine candidate complements Sanofi's position in respiratory vaccines and expands its capabilities in vaccine design and development. The acquisition is expected to increase physician and patient choice in RSV and HMPV treatment.